# SMV + SOF With/Without RBV for IFN-II Patients With CHC

> **NCT02214420** · PHASE4 · COMPLETED · sponsor: **SC Liver Research Consortium, LLC** · enrollment: 24 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Simeprevir
- **DRUG:** Sofosbuvir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02214420
- **Lead sponsor:** SC Liver Research Consortium, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2018-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02214420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02214420, "SMV + SOF With/Without RBV for IFN-II Patients With CHC". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02214420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*